Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.
暂无分享,去创建一个
J. Doroshow | M. Slovak | F. Appelbaum | C. Willman | D. Head | K. Kopecky | R. Dorr | A. List | D R Head | F R Appelbaum | C L Willman | K J Kopecky | C. Karanes | D L Persons | H E Hynes | C Karanes | A F List | M L Slovak | R Dorr | J H Doroshow | M Shurafa | D. Persons | H. Hynes | M. Shurafa | J. H. Doroshow | Alan F. List | David R. Head | Diane L. Persons | Robert T. Dorr | Harry E. Hynes | Muhammad Shurafa | Frederick R. Appelbaum | J. Doroshow
[1] P. Workman,et al. Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. , 1989, Biochemical pharmacology.
[2] W. Dalton,et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] T. Grogan,et al. Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML). , 1996, Leukemia research.
[4] A. Tomida,et al. Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance. , 1993, Journal of the National Cancer Institute.
[5] M. Slovak,et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study , 2000 .
[6] R. L. Felsted,et al. P-glycoprotein-independent mechanism of resistance to VP-16 in multidrug-resistant tumor cell lines: pharmacokinetic and photoaffinity labeling studies. , 1990, Molecular pharmacology.
[7] T. Tsuruo,et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. , 1992, Blood.
[8] M. Boiocchi,et al. Increased chemosensitivity to doxorubicin of intrinsically multidrug-resistant human colon carcinoma cells by prolonged exposure to verapamil. , 1993, European journal of cancer.
[9] D. Ross,et al. Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL. , 1994, Blood.
[10] S. Murray,et al. Enhancement by cyclosporin A of daunorubicin efficacy in Ehrlich ascites carcinoma and murine hepatoma 129. , 1987, Cancer research.
[11] O. Haas,et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. , 1991, Journal of the National Cancer Institute.
[12] F. Appelbaum,et al. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases. , 1995, Blood.
[13] T. Grogan,et al. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] F. Behm,et al. Cyclosporin A induces apoptosis in childhood acute lymphoblastic leukemia cells. , 1998, Blood.
[15] B. Sikic,et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] C. Tangen,et al. A Southwest Oncology Group study , 1993 .
[17] C. Cass,et al. Effect of duration of exposure to verapamil on vincristine activity against multidrug-resistant human leukemic cell lines. , 1989, Cancer research.
[18] G. M. Wilson,et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. , 1994, Cancer research.
[19] Iscn. International System for Human Cytogenetic Nomenclature , 1978 .
[20] I. Pastan,et al. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[21] S. Bates,et al. P‐glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines , 1991, International journal of cancer.
[22] G. Marit,et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. , 1995, Leukemia.
[23] S. Pocock,et al. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.
[24] T. Grogan,et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. , 2001, Blood.
[25] M. Slovak,et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.
[26] S. Gupta,et al. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. , 1986, The Journal of clinical investigation.
[27] D.,et al. Regression Models and Life-Tables , 2022 .
[28] R. Beuscart,et al. Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases , 1989, British journal of haematology.
[29] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[30] B. Sikic,et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] S. Michelson,et al. Drug resistance-reversal strategies: comparison of experimental data with model predictions. , 1991, Journal of the National Cancer Institute.
[32] E. Solary,et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. , 1996, Blood.
[33] V. Ling,et al. Identification of members of the P-glycoprotein multigene family , 1989, Molecular and cellular biology.
[34] J. Ordonez,et al. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. , 1993, Blood.
[35] E. Estey,et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. , 1999, Blood.
[36] A. List,et al. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. , 1996, Leukemia.
[37] David R. Cox. The analysis of binary data , 1970 .
[38] A. Fojo,et al. Expression of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells. , 1995, British Journal of Cancer.
[39] M. Sehested,et al. Relationship of VP-16 to the Classical Multidrug Resistance Phenotype1 , 2006 .
[40] H. Garewal,et al. Expression of the multidrug resistance gene product (P‐glycoprotein) in myelodysplasia is associated with a stem cell phenotype , 1991, British journal of haematology.
[41] S. Ergün,et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. , 1997, Blood.
[42] L. Doyle,et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[43] J. Endicott,et al. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance , 1986, Nature.
[44] T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.
[45] K. Brouwer,et al. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver. , 1998, Cancer research.
[46] M. Slovak,et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.
[47] C. Bloomfield,et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] E. Estey,et al. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] D. Ribatti,et al. Antiangiogenesis by cyclosporine. , 1998, Experimental hematology.
[50] I. T. Young. Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. , 1977, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[51] P. Sonneveld,et al. Overexpression of the MDRL gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin‐A , 1990, International journal of cancer.